The term "Personalized medicine" is used quite loosely; it basically refers to the use of genetics or other biomarker data to guide patient treatment decisions. These decisions I involve determining which patients should receive particular medicines or quantities of a given drug, or which patients should be given closer monitoring because they are more likely to experience a certain safety risk. The study of genetic variants and their impact on how individuals respond to pharmaceuticals has been referred to as genetics, pharmacogenetics, personalised medicine, and pharmacogenomics. Let's look at how we now treat patients to better appreciate the potential of pharmacogenomics. In the event that you visit the practitioner for high blood pressure, for instance, he or she may likely prescribe you any of a variety of blood pressure drugs based on very little knowledge of what will be effective for you. In fact, you might not even have a good reason for receiving that particular prescription other than the fact because your coverage supports it or because the doctor has some samples on hand. If the prescription doesn't start working after 4 to 6 weeks, it can be changed, or another medication might be given on base of the first.
Submit your abstract Today
